Abstract
Treatment with radiolabeled somatostatin analogs is a promising tool in the management of patients with inoperable or metastasized neuroendocrine tumors. Symptomatic improvement may occur with all (111)Indium-, (90)Yttrium-, or (177)Lutetium-labeled somatostatin analogs used for peptide receptor radionuclide therapy. If kidney protective agents are used, the side-effects are few and mild, and the median duration of the therapy response is 30 and 40 months, respectively. Overall survival is several years from diagnosis. These data compare favorably with the limited number of alternative treatments. If more widespread use of PRRT can be guaranteed, such therapy may become the therapy of first choice.
Copyright © 2011 Elsevier Inc. All rights reserved.
MeSH terms
-
Animals
-
Antineoplastic Agents / therapeutic use
-
Gastrointestinal Neoplasms / diagnosis
-
Gastrointestinal Neoplasms / diagnostic imaging*
-
Gastrointestinal Neoplasms / mortality
-
Gastrointestinal Neoplasms / radiotherapy
-
Humans
-
Indium Radioisotopes / therapeutic use
-
Lutetium / therapeutic use
-
Molecular Targeted Therapy / methods*
-
Neuroendocrine Tumors / diagnosis
-
Neuroendocrine Tumors / diagnostic imaging*
-
Neuroendocrine Tumors / mortality
-
Neuroendocrine Tumors / radiotherapy
-
Octreotide / analogs & derivatives
-
Octreotide / therapeutic use
-
Pancreatic Neoplasms / diagnosis
-
Pancreatic Neoplasms / diagnostic imaging*
-
Pancreatic Neoplasms / mortality
-
Pancreatic Neoplasms / radiotherapy
-
Radioisotopes / therapeutic use
-
Radionuclide Imaging
-
Radiopharmaceuticals / therapeutic use*
-
Receptors, Somatostatin / antagonists & inhibitors*
-
Yttrium Radioisotopes / therapeutic use
Substances
-
Antineoplastic Agents
-
Indium Radioisotopes
-
Radioisotopes
-
Radiopharmaceuticals
-
Receptors, Somatostatin
-
Yttrium Radioisotopes
-
Lutetium
-
Octreotide